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I n t r o d u c t i o n.  Soft tissue sarcomas (STS) in children and adolescents account for approximately 5% of all malignant
neoplasms diagnosed in Poland each year. Histologically and clinically they are a heterogeneous group of malignant solid
tumours. Although we have observed a remarkable progress in the therapy of childhood STS in recent decades there remain
many controversies as to how STS-patients with distant metastases should be stratified and treated. The aim of this study was
to present the 12-years experiences of the Polish Paediatric Solid Tumors Group in the treatment of children suffering from
metastatic soft tissue sarcomas.
M a t e r i a l  a n d  m e t h o d s.  All patients were enrolled into the study between 1991 and 2002 in 11 centres belonging to the
PPSTG. The children were treated according to the SIOP-MMT-91 protocol (23 patients) or according to CWS-96 protocol
(35 patients). Their age ranged between 1 and 217 months. The diagnosis was undifferentiated rhabdomyosarcoma in 4 cases,
23 embryonal rhabdomyosarcoma in 4 cases, alveolar rhabdomyosarcoma in 18 cases, PNET in 9 cases, EES in 1 case and
sarcoma synoviale in 2 cases. The most common localisations of distant metastases were non-regional lymph nodes and lungs.
Median follow up for all patients was 36 months (range: 22 to 118 months) and for surviving patients - 35 months (range: 25
to 118 months). 
R e s u l t s .  Estimated 5-year event free survival for all patients was 0.26 and estimated 5-year overall survival was 0.33.
Complete remission was achieved by 37 patients (63.8%). The comparison of EFS between the patients treated with different
protocols revealed significantly better results for the CWS-96 protocol (p<0.005). Prognosis was also evaluated according to
diagnosis, age, localisation and number of metastases. Although no parameter did significantly influence the patient outcome
alone, we did observe that patients with RME, below 10 years of age and with solitary metastases, but with the exception of
patients with bone and bone marrow metastases, had better prognosis when all these parameters were considered together
(p=0.03).
C o n c l u s i o n s.  We were able to demonstrate that patients with metastatic sarcomas could be subdivided according to
prognosis, and therefore a new stratification system should be developed for this group of patients. Patients with very poor
prognosis need new therapy strategies as those currently employed are totally ineffective.
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Introduction
Soft tissue sarcomas (STS) in children and adolescents
account for approximately 5% of all malignant neoplasms
diagnosed in Poland each year in Poland [1]. This number
has practically remained unchanged over the past several
years, as sarcomas continue to account for 1% of all newly
diagnosed adult cancers. Unfortunately, for patients who
have metastatic disease at diagnosis the outlook remains
poor despite the use of contemporary multiagent
chemotherapy, radiotherapy, and surgery and the addition
of new agents and intensification of therapy with known
active agents [2]. Disease-free survival and overall
survivalremain disappointing in the case of children with
metastatic STS at diagnosis.
The current classification system for sarcomas is still
a work in progress covering a heterogenous group of
malignant solid tumors. Newer classification systems seek
to identify the cell of origin (ie, adipocytic, myogenic,
vascular, neural, fibroblastic, chondrocytic, osteogenic,
or other). But in the long run, does this serve any useful
purpose? Tuveson and Fletcher contend that there are
distinct differences in outcome between myogenic and
nonmyogenic tumors [3]. Histologic grades within
a specific subtype, namely liposarcomas, have a significant
bearing on 5-year survival outcomes, 90% for patients
with well-differentiated tumors vs 20% for those with
pleomorphic liposarcomas.
According to the response to therapy, this very
heteregenous group of malignancies has, from the clinical
point of view, been divided into 2 subgroups. Survival is
still the ultimate proof of treatment efficacy. The
following tumours are listed as chemosensitive neoplasms
by some authors: rhabdomyosarcoma (RMS), Ewing
family tumors (extraosseus Ewing’s sarcoma – EES, and
peripheral neuroectodermal tumor – PNET) including
synovial sarcoma (SS) [2] while the STS are considered
chemotherapy-resistant and usually chemotherapy is not
used as a first line treatment in this subpopulation of
patients [2].
Here, we present the 12-year experience of the
Polish Paediatric Solid Tumors Group (PPSTG), analysing
the patterns of disease extent, response to treatment, and
survival rates in children with chemosensitive STS in stage
IV. The study was undertaken in order to evaluate the
results of treatment and to define the clinical factors
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Table I. Clinical characteristics of studied patients
Characteristics All patients SIOP-MMT-91 CWS-96
N (%) N (%) N (%)
Age:
≤10 years 23 (39.7) 10 (43.5) 13 (37.1)
>10 years 35 (60.3) 13 (56.5) 22 (62.9)
Gender:
Males 32 (55.2) 12 (52.2) 20 (57.1)
Females 26 (44.8) 11 (47.8) 15 (42.9)
Diagnosis:
RMU 4 (6.9) 0 (0) 4 (11.4)
RME 23 (39.7) 13 (56.4) 10 (28.6)
RMA 18 (31.0) 7 (30.4) 11 (31.4)
PNET 9 (15.5) 1 (4.4) 8 (22.9)
EES 1 (1.7) 1 (4.4) 0 (0)
SS 3 (5.2) 1 (4.4) 2 (5.7)
Primary localization:
orbit 1 (1.7) 0 (0) 1 (2.8)
head/neck parameningeal 10 (17.2) 8 (34.8) 2 (5.7)
head/neck non-parameningeal 1 (1.7) 1 (4.4) 0 (0)
bladder/prostate 5 (8.6) 0 (0) 5 (14.3)
genito-urinary tract without bladder/prostate 6 (10.3) 3 (13.0) 3 (8.6)
extremities 19 (32.8) 8 (34.8) 11 (31.4)
others 16 (27.6) 3 (13.0) 13 (37.2)
Tumor status (T):
T1 8 (13.8) 5 (21.7) 3 (8.6)
T2 47 (81.0) 16 (69.6) 31 (88.6)
TX 3 (5.2) 2 (8.7) 1 (2.8)
Tumor size:
a (<5 cm) 10 (17.2) 4 (17.4) 6 (17.1)
b (≥5 cm) 45 (77.6) 18 (78.2) 27 (77.2)
x 3 (5.2) 1 (4.4) 2 (5.7)
Regional lymphnode status:
N0 20 (34.4) 6 (26.1) 14 (40.0)
N1 27 (46.6) 14 (60.9) 13 (37.1)
NX 11 (19.0) 3 (13.0) 8 (22.9)
RMU – undifferentiated rhabdomyosarcoma, RME – embryonal rhabdomyosarcoma, RMA – alveolar rhabdomyosarcoma,
PNET – primary neuroectodermal tumor, EES – extraosseus Ewing’s sarcoma, SS – synovial sarcoma
influencing the prognosis in the management of STS
patients with distant metastases.
Material and method
Pa t i e n t s
Patients below 19 years of age diagnosed in 11 pediatric oncology
centres belonging to the PPSTG were eligible for study entry if
they had newly diagnosed, histologically proven distant
metastatic STS on presentation. The histologic diagnosis was
confirmed by two independent pathologists. Protocol treatment
was required to begin within 28 days of the definitive surgical
procedure (eg, biopsy). Patients were treated mainly using
multimodality therapeutic approaches, including surgery,
chemotherapy and radiotherapy. The reatment protocol
scheduled for 23 patients was the SIOP-MMT-91 (used between
1991 and 1996) [4], while the remaining 35 patients were treated
according to the CWS-96 protocol (between 1996 and 2002)
[5]. Patients treated according to the SIOP-MMT-91 protocol
received chemotherapy including: carboplatin, epirubicin,
vincristine, ifosfamide, actonomycin D and etoposide. The
response to primary chemotherapy was evaluated after 9 weeks
of treatment and second surgery was recommended if a residual
tumour had been found. Radiotherapy was administered,
concomitantly with chemotherapy in patients with micro- or
macroscopically incomplete resection in a recommended dose of
40 Gy or 54.5 Gy using a hyperfractionated, accelerated
modality. High-dose chemotherapy with melphalan, followed
by haemopoietic stem cell rescue has been used in all metastatic
patients. In the CWS-96 protocol these patients received the 6-
drug regimen CEVAIE (carboplatin, epirubicin, vincristine,
ifosfamide, actonomycin D and etoposide). After local therapy
(second surgery and/or radiotherapy- 45 Gy) in 10-13 weeks the
patients were randomized to receive either a 6-month
maintenance oral therapy with trofosfamide/epirubicin/etoposide
or a double high-dose consolidation with etoposide/melphalan or
cyclophosphamide/thiothepa.
From January 1991 through December 2002 – 58 patients
were enrolled, 32 boys and 26 girls. The characteristics of the
eligible patients are depicted in Table I. Median age at diagnosis
was 141 months, range: 1 – 217 months, accounting for 18.9% of
all patients with STS registered in the study. Almost half of the
patients had RMS (4 patients – 6.9% undifferentiated
rhabdomyosarcoma (RMU), 23 patients – 39.7% – embryonal
rhabdomyosarcoma (RME), 18 patients – 31% alveolar
rhabdomyosarcoma (RMA), 9 patients (15.5%) PNET, 1 patient
(1.7%) EES, and 3 patients (5.2%) SS. Major sites of metastatic
disease at diagnosis included: non-regional – distant nodes
(n=21), lung (n=20), bone (n=17), bone marrow (n=11) and
pleura (n=4). Approximately 80% of the patients presented
with tumors of more than 5 cm in diameter. More than 80% of
these patients had two or more metastatic sites at the time of
diagnosis (Table II).
The median follow-up for all patients was 36 months
(ranging from 22 to 118 months) and for surviving patients –
35 months (ranging from 25 to 118 months).
S t a t i s t i c a l  c o n s i d e r a t i o n s
Data available by May 2002 was retrospectively analysed using
the Statistica® 97 PL for Windows software. All patients were
followed-up for survival (time from start of treatment to death)
and failure-free survival (FFS; time from start of treatment to
the first occurrence of progression, relapse after response, or
death from any cause). Estimates of the time-to-event
distributions were calculated using the Kaplan-Meier method,
and confidence intervals (CIs) for specific estimates of time-to-
event distributions were calculated using Greenwood’s formula
for the variance of the estimates. Comparisons of outcome
among responders and nonresponders were made using the log-
rank test. For mulivariative analysis, Cox’s regression model
was used. A p value of less than 0.5 was considered statistically
significant [6, 7].
Results
The estimated 5-year event free survival for all patients
was 0.26 (Figure 1) and estimated 5-year overall survival
was 0.33. Complete remission was achieved by 37 patients
(63.8%) (Table III). The percentage of children who
achieved complete remission was similar in both protocol
groups (SIOP-MMT-91 and CWS-96). However, the
comparison of EFS between the patients treated with
different protocols revealed significantly better results of
therapy in the group treated according to the CWS-96
protocol (EFS estimated after 50 months were 0.13 for
the SIOP-MMT-91 group and 0.32 for the CWS-96 group,
p<0.005) (Figure 2). Of the 58 patients, 13 individuals
(22.4%) did not respond to the therapy (7/23 in the SIOP-
MMT-91 subgroup and 6/35 in the CWS-96 subgroup)
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Table II. Localization of distant metastases
Localization Number of patients
Non-regional lymphnodes 21
Lungs 20
Bones 17
Bone marrow 11
Liver 4
Pleura 4
Subcutaneous 3
Central nervous system 2
Peritoneal 1
Mediastinal 1
Pelvic 1
Table III. Treatment results of children with soft tissue sarcomas
in stage IV
All patients SIOP MMT-91 CWS-96
N (%) N (%) N (%)
Number of patients 58 (100) 23 (100) 35 (100)
Complete remission CR 37 (63.8) 14 (60.9) 23 (65.7)
Relapse (all): 17* (45.9) 10* (71.5) 7* (30.4)
– local 5* (13.5) 4* (28.6) 1* (4.3)
– metastatic 4* (10.8) 2* (14.3) 2* (8.7)
– mixed 8* (21.6) 4* (28.6) 4* (17.4)
Patients alive in CR1 19* (51.4) 3* (21.4) 16* (69.6)
Tumour progression 13 (22.4) 7 (30.4) 6 (17.1)
Partial remission 8 (13.8) 2 (8.7) 6 (17.1)
Toxic death 6** (10.3) 4 (17.4) 2 (5.7)
Patients alive 26 (44.8) 4 (17.4) 22 (62.9)
* Percentage of patients who achieved complete remission; 
** Causes of death: intracranial bleeding (1 patient), acute
cardiotoxicity (1 patient), cerebral oedema (1 patient), death after
implantation of Pudenze valve (1 patient), acute respiratory
distress syndrom (1 patient), septicaemia (1 patient)
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Figure 1. Event free survival of children suffering from soft tissue sarcomas with distant
metastases
Figure 2. Comparison of event free survival between patients treated 
according to the SIOP-MMT-91 protocol and the CWS-96 protocol
Figure 3. Influence of radiotherapy on the final treatment results. Rtx – radiotherapy
and died due to disease progression (Table III). It must be
stressed that radiotherapy seemed to be an important
component of successful therapy (Figure 3).
Interestingly, parameters which are normally
regarded as prognostic indicators for localised STS, did
not influence the prognosis of patients with distant
metastases: primary tumor size (<5 cm vs. ≥5 cm, 5-years
EFS: 0.31 vs. 0.27 respectively; p=0.85), regional
lymphnode involvement (regional lymphnodes involved
vs. regional lymphnodes not involved, 5-years EFS 0.25 vs.
0.26: respectively; p=0.51), resection of primary tumor
(biopsy vs. primary resection, 5 years EFS: 0.22 vs. 0.38
respectively; p=0.28), and primary localisation of tumor
(none primary localisation had better outcome than
others – data not shown). As the standard stratification
parameters were not well suited for patients in stage IV,
we attempted to assesswhether these patients were
a homogenous group with generally poor prognosis or if
the patients could have been divided into subgroups with
better and poorer outcome. For this reason we employed
a stratification system proposed by Klingebiel [9] with
some modifications (Table IV). The prognosis was
evaluated according to histology, age, and localisation
and number of metastases. Although no parameter did
significantly influence patient outcome alone, it was
observed, that patients with RME (Figure 4), aged below
10 years (Figure 5) and with solitary metastases, except
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Figure 4. Outcome of children with metastatic sarcomas according to the histology. 
RME – embryonal rhabdomyosarcoma
Table IV. Risk factors in patients with distant metastases
Parameter Score 0 Score 1
Histology RME Other than RME
N=23 N=35
Age ≤10 years old >10 years old
N=23 N=35
Localization Solitary metastases Bones, bone marrow or 
of metastases (except bone and bone multiple metastases
marrow metastases)
N=24 N=34
RME – embryonal rhabdomyosarcoma
Figure 5. Outcome of children with metastatic sarcomas according to patient age
for patients with bone and bone marrow metastases
(Figure 6), had better prognosis. Moreover, when all
these parameters were considered simultaneously, it was
noted that patients with 2 (23 patients) or 3 (15 patients)
of the disadvantageous clinical factors mentioned above
had significantly poorer prognosis than patients with none
(6 patients) or with only one (14 patients) disadvan-
tageous parameter (estimated EFS after 50 months
of observations: 0.08 vs. 0.51 respectively; p=0.03)
(Figure 7).
M u l t i v a r i a t i v e  a n a l y s i s
The type of protocol (SIOP-MMT-91 versus CWS-96),
the stratification system (0-1 score versus 2-3 scores) and
treatment with radiotherapy (given versus not given) were
entered as covariates in Cox’s regression model for EFS.
The model revealed type of treatment and scoring
achieved in the new stratification system as significant
independent prognostic factors (Table V). When the
parameters included in the stratification system were
added to the Cox’s regression model, they were all not
statistically significant, and the type of treatment and
scoring remained independent prognostic factors (data
not shown).
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Table V. Multivariative analysis of event-free survival 
(Cox regression model)
Covariate b p
Applied therapy SIOP-MMT-91 vs. CWS-96 -1.31 0.0003
Stratification system 0-1 score vs. 2-3 scores 1.23 0.003
Radiotherapy Given vs. not given -0.31 0.37
Figure 7. Event-free survival for children divided in 2 subgroups 
according to the stratification system presented in Table IV
Figure 6. Outcome of children with metastatic sarcomas according to the number and
localizations of metastases
Discussion
Although paediatric STS has a more favorable prognosis
than its adult counterpart, still the treatment results in
patients with distant metastases remain unsatisfactory.
In this series, the tumor size correlated with metastatic
disease at the onset and is the major factor influencing
survival. Surgery is the mainstay of therapy. The
effectiveness of adjuvant therapy remains to be
established, though radiotherapy may be advisable in
cases of inadequate surgery.
EFS reported for children and adolescence with
metastatic STS is not better than 26-28% after a 5-year
observation period [8-11], which corresponds with our
results achieved by the PPSTG. Although the different
long term outcomes with the CWS-96 protocol for STS in
stage IV could not be definitely assessed because of the
relatively short follow-up time, some preliminary
observations could be made. A comparison of these two
treatment protocols (SIOP-MMT-91 and CWS-96) reveals
significantly better results in patients tretated with the
CWS-96 protocol. Speculating as the cause of this
discrepancy one could explain it by another strategy
employed after the initial phase of intense chemotherapy.
Patients treated according to the SIOP-MMT-91 protocol
were stipulated to go through autogenic bone marrow
transplantation (ABMT) or peripheral blood stem cell
transplantation (auto-PBSCT) after high dose chemo-
therapy (HDC/T). Such a treatment caused deep
immunosupression by ablating all inherited and acquired
anti-tumor immunity. Presuming that high dose
chemotherapy is not able to destroy all the tumor cells,
a single surviving malignant cell had a good chance to
develop during this deep immunosupression. The
observation that most relapses occurred within 8 months
after ABMT or auto-PBSCT, is in favour of this
hypothesis. Similar facts were reported by other authors
[12-17]. Most patients treated with the CWS-96 protocol
were after intensive chemotherapy treated with so-called
low-dose intensity maintainance chemotherapy [5]. Such
a treatment could prolong EFS in metastatic STS.
However, these observations are restricted to a relatively
short follow-up time and final conclusions will be available
after a longer period.
Patients with metastatic sarcomas are generally
considered to be a homogenous group with a very poor
prognosis. We were able to demonstrate that this
population could be further divided into two sub-
populations with relatively better outcomes a 5-year EFS
estimate of approx. 50%) or with a very poor prognosis
having a survival ratio below 10% after a 5-year
observation time. Such a stratification system could be
a useful tool for the further assessment of children with
metastatic soft tissue sarcomas. In the group with
relatively good prognosis optimising the therapy could
reduce the early and late side-effects [18-20]. Neoadjuvant
chemotherapy and/or radiation therapy confers to
substantial benefit following complete surgical resection
of localized disease. The management goals of metastatic
sarcomas was claimed to be palliative, since these
advanced malignancies are virtually always incurable, in
spite of high-dose chemotherapy, highly toxic combination
chemotherapy, and surgical intervention. It is very
important to underline, that there is an urgent need to
search for other therapy methods for patients with 2 or 3
unfavourable scores. For this subgroup of patients the
currently used treatment regimens are ineffective and
new drugs or a different approach is needed. Agents that
have shown the most activity in treating STS include
doxorubicin and ifosfamide. Topotecan, vinblastine,
paclitaxel, docetaxel, dacarbazine, gemcitabine, and
carboplatin have also shown some degree of efficacy [21].
The targeted molecular therapies of the present may be
well suited for treating sarcomas, given the fact that many
sarcoma-linked oncogenes appear to be triggered by
viruses, including the Rous sarcoma virus. The sequencing
of these viruses may allow to develop specific antibodies
against oncogenic activation. Probably the most exciting
recent advance in the treatment of sarcomas has been
the effect of imatinib/STI571 on GISTs, which, heretofore,
have been notoriously resistant to chemotherapy [22].
The expression of platelet-derived growth factor beta in
dermatofibrosarcoma tuberans is also being investigated
as a target for imatinib/STI571 therapy [22, 23]. The rapid
identification and testing of promising new therapies is
urgently needed to improve the outcomes of children
with disseminated disease. We have a long way to go
before the lethal natural histories of these tumors are
radically altered.
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